ProCE Banner Activity

CE / CME

New Options in High-Risk Early Breast Cancer

Video

On-demand recording of the PCE Oncology Fall Conference expert faculty presentation and case discussion on the current landscape of high-risk early breast cancer and newly available options for treatment.

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: December 11, 2023

Expiration: December 10, 2024

Share

Faculty

Kevin Kalinsky

Kevin Kalinsky, MD, MS

Professor of Medicine
Director, Glenn Family Breast Center
Winship Cancer Institute
Emory University
Atlanta, Georgia

Kathleen Madden

Kathleen Madden, FNP, MSN, AOCNP, APHN

Melanoma Program
NYU Langone Perlmutter Cancer Center
New York, NY

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

Supported by educational grants from Merck Sharp & Dohme, LLC and AstraZeneca.

AstraZeneca

Merck Sharp & Dohme, LLC

Target Audience

The proposed educational program is planned for and will be targeted to oncology NPs, PAs, and nurses who manage patients with breast cancer.

Program Learning Goal

The goal of this continuing education activity is to improve oncology NP and PA knowledge and skills related to integration of recommended therapies for high-risk EBC into patient care and to competency in managing toxicities of recommended therapies to optimize patient outcomes.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess clinical trial evidence for targeted oral therapies in adjuvant treatment of high-risk early breast cancer

  • Formulate evidence-based individualized treatment plans for use of targeted oral therapies in high-risk early breast cancer

  • Apply recommendations to manage toxicities associated with oral targeted therapies in high-risk early breast cancer

  • Apply recommended management strategies for AEs associated with BTK inhibitors

Disclosure

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Kevin Kalinsky, MD, MS

Professor of Medicine
Director, Glenn Family Breast Center
Winship Cancer Institute
Emory University
Atlanta, Georgia

Kevin Kalinsky, MD, MS: consultant/advisor/speaker: 4D Pharma, AstraZeneca, Daiichi Sankyo, Genentech/Roche, Immunomedics, Lilly, Menarini, Merck, Mersana, Myovant, Novartis, Oncosec, Puma, SeaGen, Silicon Biosystems, Takeda; researcher: Ascentage, AstraZeneca, Genetech/Roche, Lilly, Novartis, SeaGen.

Kathleen Madden, FNP, MSN, AOCNP, APHN

Melanoma Program
NYU Langone Perlmutter Cancer Center
New York, NY

Kathleen Madden, FNP, MSN, AOCNP, APHN, has no relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 11, 2023, through December 10, 2024:

  1.  Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

A picture containing logoDescription automatically generated

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacology credit.

Physician Associate Continuing Medical Education

AAPAPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until December 10, 2024. PAs should only claim credit commensurate with the extent of their participation.

 

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.